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Insulin Resistance Is Highly Prevalent
and Is Associated With Reduced Exercise
Tolerance in Nondiabetic Patients With Heart Failure
Matlooba A. ALZadjali, MD, MPH, Valerie Godfrey, PHD, Faisel Khan, PHD,
AnnaMaria Choy, FRCP, FACC, Alexander S. Doney, MD, Aaron K. Wong, MBCHB, MRCP,
John R. Petrie, MD, FRCP, Allan D. Struthers, MD, FRCP, Chim C. Lang, MD, FACC
Dundee, United Kingdom
Objectives The purpose of this study was to establish the prevalence of insulin resistance (IR) among nondiabetic chronic
heart failure (CHF) patients and to seek factors associated with IR in CHF, including the relationship of IR to
functional class, exercise capacity, and disease severity in CHF.
Background Several lines of evidence suggest that CHF is an IR state. The prevalence of IR in CHF and its relation to CHF
have not been fully defined.
Methods Fasting insulin resistance index (FIRI) was assessed in a cohort of 129 consecutive CHF patients (mean age
69.2  10.4 years; 76% males; body mass index 27.4  4.4 kg/m2). Patients underwent cardiopulmonary exer-
cise testing and peripheral endothelial function testing by reactive hyperemia peripheral arterial tonometry
(RH-PAT).
Results Prevalence of IR as defined by FIRI 2.7 was 61% in our cohort of CHF patients. There was a significant correla-
tion between IR and waist circumference (r  0.37; p  0.01), serum triglycerides (r  0.34; p  0.01), high-
density lipoprotein cholesterol (r  0.22; p  0.02), and serum leptin (r  0.39; p  0.03). Insulin resistance
increased significantly with worsening New York Heart Association functional class (p  0.01). The CHF patients
with IR had a significantly lower exercise capacity and peak oxygen consumption than patients with an FIRI
2.7. The RH-PAT ratio was significantly lower in CHF patients with IR compared with CHF patients with an FIRI
2.7 (1.6  0.3 vs. 2.0  0.5; p  0.05).
Conclusions Insulin resistance is highly prevalent among nondiabetic CHF patients and is associated with decreased exercise
capacity in patients with CHF. (Insulin Resistance: Heart Failure; NCT00486967). (J Am Coll Cardiol 2009;53:
747–53) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.081a
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phere are several lines of evidence that suggest that chronic
eart failure (CHF) is an insulin resistant (IR) state (1).
linical studies using hyperinsulinemic-euglycemic clamps
ave previously demonstrated fasting hyperinsulinemia and
R in patients with both ischemic and nonischemic CHF
2–4). These correlative studies, however, do not exclude
he possibility that many such patients may have IR prior to
eveloping left ventricular (LV) systolic dysfunction. Fur-
her evidence for CHF as an IR state comes from studies
ith the pacing heart-failure dog model whereby conscious,
hronically instrumented dogs were shown to develop IR
rom the Division of Medicine & Therapeutics, University of Dundee, Ninewells
ospital and Medical School, Dundee, United Kingdom. This study was funded in
art by grants from the British Heart Foundation (grant number PG/06/143/21897)
nd DDS Thorntons.a
Manuscript received March 13, 2008; revised manuscript received August 14, 2008,
ccepted August 18, 2008.nd insulin signaling abnormalities during the evolution of
HF (5). The exact mechanisms of IR in CHF are not
nown. Besides the loss of skeletal muscle bulk and skeletal
lood flow, sympathetic overactivity, proinflammatory cyto-
ines, altered adipokines, and endothelial dysfunction have
een implicated in the pathophysiology of IR in CHF (6,7).
See page 763
The prevalence of IR in the CHF population has not
een fully defined. Neither do we know the clinical
ssociations of IR in patients with CHF. The aim of this
tudy was to investigate the prevalence of IR among
ondiabetic CHF patients, utilizing the fasting insulin
esistance index (FIRI), which is derived from fasting
lasma insulin and glucose levels and has been validated
gainst the hyperinsulinemic-euglycemic clamp (8). We
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ated with IR in CHF, including
the relationship of IR to func-
tional class and exercise capacity.
Methods
Study subjects. CHF patients
were identified from inpatients as
well as patients attending outpa-
tient clinics and from the general
practice in the community. Diag-
nosis of CHF was based on the
European Society of Cardiology
guidelines for CHF (i.e., symp-
toms of CHF and objective evi-
dence of LV systolic dysfunction)
(9). All patients with stable CHF
were included in the study. Inpa-
tients with CHF who were hospi-
talized were also included, except
atients with acutely decompensated CHF requiring intrave-
ous therapy. CHF patients with a previous diagnosis of
iabetes mellitus or with a fasting plasma glucose level 7.0
mol/l or 126 mg/dl as defined by the American Diabetes
ssociation criteria were excluded from the study (10). For
omparison, a group of healthy subjects were also studied.
hey were recruited from the community and were clinically
ealthy based on history, physical examination, and blood
aboratory results and were not taking any medication. All
atients and healthy volunteers provided written informed
onsent for participation in this study, which was approved by
he Tayside Committee on Medical Research Ethics.
tudy protocol. On the day of study, all subjects were in a
asting state. Following physical examination and determina-
ion of their New York Heart Association (NYHA) functional
lass, anthropometric measurements of fat mass and free fat
ass were made. Body fat was measured by recording height,
eight, and waist and hip circumference. An estimation of
ercent body fat and lean body mass was determined from the
um of skin-fold thicknesses measured at 4 sites (biceps,
riceps, subscapular, and suprailiac) (11,12). Thereafter, blood
as drawn following a 20-min semirecumbent rest for mea-
urement of glucose, insulin (radioimmunoassay kit, INSIK-5,
iaSorin, Berkshire, United Kingdom), plasma catechol-
mines (ESA Plasma Catecholamine Analysis Kit and HPLC,
SA Analytical Limited, Buckinghamshire, United King-
om), adiponectin, and leptin (enzyme immunoassay, Quan-
ikine, R&D Systems, Abingdon, United Kingdom).
R. Insulin resistance was measured by an empirical FIRI,
onsisting of the product of plasma insulin and glucose (8):
IRI  fasting glucose  fasting insulin/25. On the basis of
he plasma glucose concentration upper limit of normal of 6.1
mol/l and our laboratory’s upper limit of normal for plasma
Abbreviations
and Acronyms
BMI  body mass index
CHF  chronic heart failure
CI  confidence interval
FIRI  fasting insulin
resistance index
HDL  high-density
lipoprotein
IR  insulin
resistance/resistant
NYHA  New York Heart
Association
OR  odds ratio
RH-PAT  reactive
hyperemia peripheral
arterial tonometry
VO2  oxygen consumptionnsulin of 11.2 mU/l, an FIRI value of 2.7 was determined as Rhe upper limit of normal. An individual with an FIRI 2.7
as considered to have IR (8,13).
ardiopulmonary exercise testing. The CHF patients
nderwent cardiopulmonary exercise testing utilizing incre-
ental cycle ergometry with continuous expired gas analysis
hroughout the test with the Innocor System (Innocor
ebreathing system, Innovision A/S, Odense, Denmark) as
reviously described (14). The Innocor system uses an
xygen-enriched mixture of an inert soluble gas (0.5%
itrous oxide) and an inert insoluble gas (0.1% sulfur
exafluoride) from a 4-l pre-filled anesthesia bag that allows
he determination of oxygen consumption (VO2), metabolic
easurements, and cardiac output. After 3 min of data at
est, exercise began at a workload of 0 W and increased
very 3 min by 25 W until symptom-limited maximal
xercise was reached. Patients were instructed to signal
pproximately 2 min before peak exercise. Patients per-
ormed practice exercise tests on a different day before each
ctual exercise test. Cardiac output and VO2 measurements
ere made at the end of the resting period, at 50 W, and at
eak exercise. Peak VO2 was defined as the highest value of
xygen uptake achieved in the final 20 s of exercise (14).
ndothelial function. Endothelial function was deter-
ined by reactive hyperemia-peripheral arterial tonometry
RH-PAT) (Itamar Medical Ltd., Caesarea, Israel). This is
noninvasive technique used to assess peripheral microvas-
ular endothelial function by measuring changes in digital
ulse volume during reactive hyperemia (15,16). The RH-
AT ratio was defined as the ratio between the arterial pulse
ave amplitude following a 5-min arterial occlusion in the
orearm to the pre-occlusion value (15,16). Peripheral en-
othelial function, as assessed by RH-PAT, has been shown
o be highly correlated with coronary endothelial function,
nd the endothelial function index has been validated
gainst acetylcholine-mediated vasodilatation of coronary
rteries, the gold standard in endothelial function testing
16). Although it has not been used in the setting of CHF,
he technique has been used in a broad spectrum of patients
ith cardiovascular disease (15–17). We are not aware of
pecial limitations or reliability problems in the use of this
echnique in patients with CHF.
tatistical analyses. All results are presented as mean value
D. Statistical analyses were performed with SPSS version
4 (SPSS Inc., Chicago, Illinois). Data that were deter-
ined to be not normally distributed by histogram and
onparametric test (1-sample Kolmogorov-Smirnov test)
ere log-transformed before analysis by parametric tests.
ndependent t tests were used to compare mean values
etween groups, and chi-square analyses were used for
ategorical variables. When FIRI was modeled as a con-
inuous variable, simple linear regression (least-square
ethod) and multiple linear regression analyses were
erformed to evaluate the relationship between FIRI and
ther parameters obtained from anthropometric measure-
ent, NYHA functional class, neurohormone levels, and
H-PAT. Multiple logistic regression was applied when
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March 3, 2009:747–53 Insulin Resistance and CHFIRI was modeled as a categorical variable. One-way
nalysis of variance was used to test for differences of
IRI between NYHA functional classes. A p value 0.05
as considered statistically significant.
esults
total of 525 patients were approached to participate in
his study. Of these, 281 were excluded because they had a
urrent diagnosis of diabetes, and 115 did not wish to
linical Characteristics of Study Population
Table 1 Clinical Characteristics of Study Population
Variables All CHF (n  129)
Demographic characteristics
Age (yrs) 69.2 10.4
Sex
Male 76.0%
Female 24.0%
SBP 136.6 25.7
DBP 77.3 12.8
NYHA functional class
I 9.3%
II 29.5%
III 54.3%
IV 7.0%
Etiology of HF
Ischemic 82%
Nonischemic 17.8%
Ejection fraction 26.7 6.3%
Anthropometric measurement
BMI (kg/m2) 27.3 4.4
Waist-hip ratio 0.9 0.2
% fat 31.3 7.3
% lean body mass 68.6 7.3
Laboratory measurements
Total cholesterol (mmol/l) 4.0 1.1
HDL (mmol/l) 1.4 0.4
TG (mmol/l) 1.6 0.9
Fasting blood glucose (mmol/l) 5.0 0.6
Fasting insulin (U/ml) 20.7 17.8
Neurohormones
Adiponectin (g/ml) 10.7 8.1
Leptin (ng/ml) 17.3 27.1
Norepinephrine (ng/ml) 1.1 0.9
Epinephrine (ng/ml) 0.3 0.8
Exercise measurement
Exercise time (s) 428.1 244.5
Peak VO2 (ml/kg/min) 10.9 4.1
Endothelial function
RH-PAT 1.7 0.4
Medications
ACE inhibitors 94%
Beta-blockers 78%
Diuretics 81%
Aldosterone antagonists 24%
Digoxin 10%
ata are presented as % or mean value  SD. p values indicate significant differences between g
ACE  angiotensin-converting enzyme; BMI  body mass index; CHF  chronic heart failure; DBP  d
F  heart failure; NYHA  New York Heart Association; RH-PAT  reactive hyperemia-peripheral arteriaarticipate in the study. Of the remaining 129 CHF
atients, 79 (61%) had an FIRI 2.7 and were determined
o have IR (Table 1, Fig. 1). Three of 18 healthy partici-
ants (16%) had an FIRI 2.7; they remained within the
ealthy subjects group for comparison.
Upon analysis of all patients with CHF for factors
ssociated with the development of IR by univariate logistic
egression, we found significant correlations between IR and
YHA functional class, serum triglycerides, body mass
ndex (BMI), leptin, percent fat, waist circumference, ejec-
RI >2.7 (n  79) FIRI <2.7 (n  50) p Value
67.9 9.5 69.9 11.0 NS
NS
79.0% 73.5%
21.1% 26.5%
135.1 25.5 139.7 25.9 NS
76.8 11.9 78.5 13.9 NS
2.5% 18.0% 0.05
22.7% 40%
59.4% 40%
11.3% 0.0%
80.3% 85.7% NS
19.7% 14.3%
24.7 6.1% 29.6 5.8% 0.05
29.1 4.0 25.4 3.9 0.05
0.9 0.2 0.8 0.1 NS
33.1 7.4 28.4 6.5 0.05
66.8 7.2 71.5 6.1 0.05
3.9 0.9 4.0 1.1 NS
1.3 0.3 1.5 0.4 0.05
1.8 0.8 1.3 0.5 0.05
5.2 0.7 4.6 0.4 0.05
27.5 18.7 10.3 2.7 0.05
9.4 6.3 11.8 9.1 0.05
22.1 32.6 8.9 7.2 0.05
0.9 0.7 1.2 1.1 NS
0.2 0.6 0.3 0.8 NS
330.0 162.6 626.2 262.5 0.01
8.0 1.6 15.2 2.3 0.05
1.6 0.3 2.0 0.5 0.05
93% 94% NS
78% 78% NS
85% 76% NS
30% 14% 0.05
8% 11% NSFI
roups.
iastolic blood pressure; FIRI  fasting insulin resistance index; HDL  high-density lipoprotein;
l tonometry; SBP  systolic blood pressure; TG  triglycerides; VO2  oxygen uptake.
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Insulin Resistance and CHF March 3, 2009:747–53ion fraction, percent lean body mass, high-density lipopro-
ein (HDL) cholesterol, and endothelial function as mea-
ured by RH-PAT (Table 2). Using multiple logistic
egression with the above 11 relevant factors in the patients
ith CHF, we found that NYHA functional class (odds
atio [OR]: 3.02; 95% confidence interval [CI]: 1.19 to
.67; p  0.001), triglycerides (OR: 2.81; 95% CI: 1.26 to
.26; p  0.01), BMI (OR: 1.27; 95% CI: 1.10 to 1.46;
Figure 1 Range of FIRI in Patients
With Heart Failure (n  129)
Patients were considered to be insulin resistant if they had a
fasting insulin resistance index (FIRI) 2.7. CHF  chronic heart failure.
nivariate Logistic Regression Analysis of Clinicald Humoral Factors fo Prediction of IR in Patientsith HF
Table 2
Univariate Logistic Regression Analysis of Clinical
and Humoral Factors for Prediction of IR in Patients
With HF
Variables Odds Ratio
95% Confidence
Interval p Value
NYHA functional class (severity) 3.37 (1.88–6.04) 0.01
TG (mmol/l) 2.84 (1.50–5.35) 0.01
BMI (kg/m2) 1.26 (1.13–1.40) 0.01
Sex (male) 1.25 (0.55–2.84) 0.58
Leptin (ng/ml) 1.21 (1.07–1.36) 0.01
Fat (%) 1.15 (1.10–1.21) 0.01
Waist circumference (cm) 1.02 (1.00–1.03) 0.96
Waist-hip ratio 1.02 (0.41–2.52) 0.01
Norepinephrine (ng/ml) 1.00 (0.99–1.00) 0.06
Epinephrine (ng/ml) 1.00 (0.99–1.00) 0.53
SBP (mm Hg) 0.99 (0.98–1.01) 0.74
DBP (mm Hg) 0.99 (0.97–1.02) 0.94
Age (yrs) 0.98 (0.94–1.01) 0.13
Alcohol use (yes) 0.93 (0.46–1.85) 0.84
Total cholesterol (mmol/l) 0.87 (0.61–1.23) 0.44
EF (%) 0.87 (0.81–0.93) 0.01
Adiponectin (ng/ml) 0.75 (0.53–1.05) 0.75
Smoke (yes) 0.57 (0.20–1.57) 0.27
Lean body fat (%) 0.81 (0.82–0.96) 0.01
HDL (mmol/l) 0.20 (0.07–0.59) 0.01
RH-PAT ratio 0.12 (0.04–0.36) 0.01F  ejection fraction; IR  insulin resistance; other abbreviations as in Table 1. 0.01), ejection fraction (OR: 0.82; 95% CI: 0.73 to
.92; p  0.001), HDL cholesterol (OR: 0.15; 95% CI:
.02 to 0.92; p  0.05), and RH-PAT (OR: 0.05; 95% CI:
.01 to 0.29; p  0.001) were significant and independent
redictors of IR (Table 3).
When FIRI was modeled as a continuous variable, there
ere significant univariate correlations between IR and
YHA functional class (r  0.48; p  0.01), BMI (r 
.46; p  0.01), percent fat (r  0.37; p  0.01), waist-hip
atio (r 0.37; p 0.01), triglycerides (r 0.34; p 0.01),
aist circumference (r  0.37; p  0.01), leptin (r  0.39;
 0.03), norepinephrine (r  0.25; p  0.01), and
DL (r  0.22; p  0.02). Multivariate analysis with 9
elevant factors (NYHA functional class, percent fat, BMI,
riglycerides, waist-hip ratio, central obesity, norepineph-
ine, HDL, and leptin) showed that NYHA functional class
nd BMI were significantly and independently correlated
ith insulin sensitivity (all p 0.05) in these CHF patients.
elationship of IR with functional capacity. We found
hat the mean of FIRI increased significantly with worsen-
ng NYHA functional class (p  0.01) (Fig. 2). The degree
f IR was also related to the exercise capacity and peak VO2.
total of 120 patients, 71 patients in the IR group and 49
n the normal insulin-sensitive group, were able to perform
he exercise test. The IR patients had a significantly lower
xercise duration (330.0  162.6 s vs. 626.2  262.5 s; p 
.01), peak VO2 (8.0  1.6 ml/kg/min vs. 15.2  2.3
ultiple Logistic Regression for Eachariab t Predict IR in Patients With HF
Table 3 Multiple Logistic Regression for EachVariable to Predict IR in Patients With HF
Variables Odds Ratio 95% Confidence Interval p Value
NYHA functional class 3.02 (1.19–7.67) 0.01
TG (mmol/l) 2.81 (1.26–6.26) 0.01
EF (%) 0.82 (0.73–0.92) 0.01
BMI (kg/m2) 1.27 (1.10–1.46) 0.01
HDL (mmol/l) 0.15 (0.02–0.92) 0.05
RH-PAT ratio 0.05 (0.01–0.29) 0.01
bbreviations as in Tables 1 and 2.
Figure 2 FIRI and NYHA Functional Class
FIRI  fasting insulin resistance index; NYHA  New York Heart Association.
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March 3, 2009:747–53 Insulin Resistance and CHFl/kg/min; p  0.05), and peak cardiac output (6.1  1.2
/min vs. 9.2  0.8 l/min; p  0.05) (Fig. 3). There was a
ignificant correlation between FIRI and peak VO2 (r 
0.84; p  0.01), exercise duration (r  0.54; p  0.01),
nd peak cardiac output (r  0.82; p  0.01). After
djustment for BMI and NYHA functional class, there was
correlation between FIRI and peak VO2 (r  0.83; p 
.01), exercise duration (r  0.40; p  0.01), and peak
ardiac output (r  0.76; p  0.01).
Healthy volunteer subjects with IR had lower peak VO2
Figure 3 Relationship Between Insulin
Resistance and Exercise Parameters
The exercise parameters consisted of (A) mean peak oxygen consumption
(VO2), (B) mean peak cardiac output (CO), and (C) mean peak exercise dura-
tion. FIRI  fasting insulin resistance index.16.4  1.1 ml/kg/min vs. 19.8  3.4 ml/kg/min; p  0.1) ond peak cardiac output (6.5  0.5 l/min vs. 8.9  2.4
/min; p  0.1) compared with those with normal insulin
ensitivity.
iscussion
his study had 3 main findings. First, IR as assessed by
IRI is highly prevalent (61%) in patients with CHF who
o not have a diagnosis of diabetes compared with healthy
ubjects. Second, IR was associated with increased waist
ircumference, increased serum leptin levels, and more
ronounced endothelial dysfunction in these patients. Fi-
ally, IR increased significantly with worsening NYHA
unctional class and was associated with reduced exercise
apacity and exercise duration. Importantly, this was inde-
endent from factors associated with increased IR such as
MI and serum triglycerides.
R in CHF. Previous studies involving much smaller
ohorts of patients have investigated IR in CHF, utilizing a
yperinsulinemic-euglycemic clamp, and these have gener-
lly demonstrated a reduction in insulin sensitivity and an
ncrease in fasting insulin concentration in patients with
HF (2,4). In this study, we have chosen the simple FIRI
quation and have found that IR is highly prevalent in
atients with CHF. It should be noted that a previous study
y Suskin et al. (13) also utilized FIRI to examine glucose
nd insulin abnormalities in patients with CHF. They
tudied CHF patients with diabetes mellitus as well as those
ho had no diabetes. Like us, they found a high prevalence
f patients with an FIRI 2.7: 72% among patients with
HF and diabetes and 33% among nondiabetic CHF
atients (13). Our somewhat higher prevalence of patients
ith an FIRI 2.7 might be due to our greater propor-
ion of NYHA functional class III to IV patients.
The exact mechanisms of IR in CHF are not known. A
umber of mechanisms have been proposed, including the
oss of skeletal muscle bulk and skeletal blood flow, sympa-
hetic overactivity, pro-inflammatory cytokines, altered adi-
onectin and leptin levels, and endothelial dysfunction
6,7,18,19). In the present study, we found a significant
orrelation between IR and BMI, serum triglycerides,
DL, and endothelial function. The significant correlation
ith BMI and serum lipids was not unexpected as these are
ell-established characteristics of IR and have been previ-
usly reported (6). The correlation with endothelial func-
ion is of interest and may suggest a link between endothe-
ial function and IR in CHF (20). We did not see a
elationship between IR and sympathetic activation. Pa-
lisso et al. (2) had previously demonstrated an inverse
orrelation between norepinephrine concentrations and in-
ulin sensitivity. However, this is not a universal finding. In
eeping with our finding, Swan et al. (4) did not find a
orrelation with sympathetic activity. In our study, we found
ltered adiponectin and leptin levels in patients with IR with
ignificant correlation between FIRI and the plasma levels
f leptin and adiponectin. Both leptin and adiponectin are
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Insulin Resistance and CHF March 3, 2009:747–53mplicated in the pathophysiology of IR (21,22). This
elationship between IR and leptin in CHF has previously
een described by Doehner et al. (23). These findings
ogether with our current study may suggest that leptin
ould be an important regulator of IR in CHF patients.
owever, it should be emphasized that the presence of
orrelations between variables does not prove causality.
learly, further studies are required to define the mecha-
isms underlying the pathophysiology of IR in CHF.
unctional consequences of IR in CHF. In this study, we
ound that IR was significantly correlated with peak VO2,
xercise duration, and peak cardiac output, before and after
djustment for BMI and NYHA functional class. The
esults of our study concur with others that show that the
egree of IR is associated with reduced exercise capacity and
eak VO2 in patients with CHF (2–4,13). The underlying
echanism for the decreased exercise capacity caused by IR
n CHF has not been defined. The pathophysiology of
educed exercise capacity in CHF is complex and may
nvolve central and peripheral factors (24). The heart is an
nsulin-responsive organ, and IR may cause cardiac dysfunc-
ion and impact on cardiac performance through alterations
n cardiac structure, function, and metabolism (25). In our
tudy, the cardiac output at peak exercise was lower in CHF
ith IR. Baseline cardiac output was not different, which
ay suggest that cardiac reserve may be altered in CHF
atients with IR. With respect to peripheral factors, we
ound a significant correlation between exercise capacity and
ndothelial function. This finding was not unexpected,
iven findings in previous studies in patients with CHF and
iabetes showing correlations in these disease states between
mpaired exercise capacity and reduced endothelial function
26,27). Skeletal abnormalities may also be involved. Previ-
us studies have shown that IR in CHF is closely correlated
ith a reduction in strength per unit muscle in the quadri-
eps muscle group and to maximal oxygen uptake per unit
uscle (4). Obviously, any evidence that IR causes central
ardiac dysfunction or peripheral skeletal muscle abnormal-
ties in patients with CHF must remain speculative and
annot be inferred directly from this study.
tudy limitations. First, we did not measure muscle bulk
nd muscle blood flow. However, we did measure lean body
ass, which was significantly lower in IR patients compared
ith patients with normal insulin sensitivity. Second, mea-
urement of plasma catecholamines is only an indirect
easure of sympathetic nervous system activity. Future
tudies are needed with direct measures of sympathetic
ctivity, including measurement of muscle sympathetic
erve activity, or by determination of norepinephrine turn-
ver utilizing tritiated norepinephrine spillover studies. It
hould, however, be noted that plasma catecholamine levels
o represent the neurohormonal activation in CHF and
ave consistently been shown to be an important prognostic
arker in CHF. We also acknowledge that our healthy
roup of volunteers was not matched for age, sex, and BMI.
inally, we acknowledge that in this study, we have exam-ned only for the presence of correlations between variables.
t should be emphasized that such correlations neither prove
ausality nor define the manner in which they are related,
lthough we did demonstrate that they were independent
rom established IR phenotypes such as BMI and serum
riglycerides.
onclusions
ur study suggests that there is a high prevalence of IR in
atients with CHF and that IR is independently associated
ith worsening NYHA functional class, decrease in peak
O2, decrease in exercise time, and endothelial dysfunction.
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